Tools
Tools
Cassells, Irwin, Stringer, Tameryn 
ORCID: https://orcid.org/0000-0002-4439-131X, Hutton, Alan T., Prince, Sharon and Smith, Gregory S.
(2018)
Impact of various lipophilic substituents on ruthenium(II), rhodium(III) and iridium(III) salicylaldimine-based complexes: synthesis, in vitro cytotoxicity studies and DNA interactions.
Journal of Biological Inorganic Chemistry, 23.
763–774.
ISSN 1432-1327
Abstract
A series of bidentate salicylaldimine ligands was prepared and reacted with either [RuCl(µ-Cl)(p-cymene)]2, [RhCl(µ-Cl)(Cp*)]2 or [IrCl(µ-Cl)(Cp*)]2. All of the compounds were characterised using an array of spectroscopic and analytical techniques, namely, nuclear magnetic resonance (NMR) spectroscopy, infrared (IR) spectroscopy and mass spectrometry. Single crystal X-ray diffraction (XRD) was used to confirm the bidentate coordination mode of the salicylaldimine ligand to the metal centre. The platinum group metal (PGM) complexes were screened against the MCF7 breast cancer cell line. The ruthenium and iridium salicylaldimine complexes showed comparable or greater cytotoxicity than cisplatin against the MCF7 cancer cells, as well as greater cytotoxicity than their rhodium counterparts. Three of the salicylaldimine complexes showed potent activity in the range 18–21 µM. Two of these complexes had a greater affinity for cancerous cells than for CHO non-cancerous cells (SI > 4). Preliminary mechanistic studies suggest that the ruthenium complexes undergo solvation prior to 5′-GMP binding, whereas the iridium complexes were inert to the solvation process.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being |
| Faculty \ School: | Faculty of Science > School of Chemistry |
| Related URLs: | |
| Depositing User: | LivePure Connector |
| Date Deposited: | 19 Jul 2022 13:30 |
| Last Modified: | 24 Oct 2022 16:33 |
| URI: | https://ueaeprints.uea.ac.uk/id/eprint/86605 |
| DOI: | 10.1007/s00775-018-1567-3 |
Actions (login required)
 |
View Item |